

The long-term consequences of severe acute respiratory syndrome (SARS) on lung health.

Swenson Agarwal*

Department of Medicine, University of Weill Cornell Medicine, New York, USA

Abstract

Severe Acute Respiratory Syndrome (SARS) is a highly infectious respiratory disease caused by a coronavirus that emerged in China in 2002. It spread rapidly across Asia and the world, leading to a global outbreak that lasted until 2004. The disease caused severe respiratory symptoms, including cough, fever, and shortness of breath, and had a high mortality rate, especially among older individuals and those with pre-existing health conditions.

Keywords: SARS, Respiratory disease, lungs, Pulmonary fibrosis, Respiratory failure.

Introduction

While the immediate health impacts of SARS were devastating, there is growing concern about the long-term consequences of the disease, particularly on lung health. Studies have shown that SARS survivors are at an increased risk of developing lung-related complications, including chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and respiratory failure. One of the primary mechanisms through which SARS damages the lungs is through the activation of the immune system. When the coronavirus enters the body, it triggers an immune response that leads to inflammation and damage to lung tissue. In severe cases, this inflammation can lead to the development of acute respiratory distress syndrome (ARDS), a condition in which fluid builds up in the lungs and prevents oxygen from getting into the bloodstream [1, 2].

ARDS is one of the most severe complications of SARS, and it can have long-lasting effects on lung function. Studies have shown that SARS survivors who developed ARDS have a higher risk of developing lung-related complications, including pulmonary fibrosis and respiratory failure, in the years following their recovery [3]. Pulmonary fibrosis is a condition in which scar tissue forms in the lungs, making it difficult to breathe, while respiratory failure is a life-threatening condition in which the lungs are unable to provide enough oxygen to the body. Even those who did not develop ARDS during their SARS illness may be at risk for long-term lung damage. Studies have shown that SARS survivors often have abnormalities in lung function tests, including reduced lung capacity and impaired diffusion capacity, which can persist for years after their recovery. These changes in lung function may not be immediately noticeable, but they can increase the risk of developing lung-related complications later in life [4].

Another concern is the potential for SARS to increase the risk of COPD, a chronic lung disease that is characterized by a persistent cough, shortness of breath, and difficulty breathing. COPD is caused by long-term exposure to harmful particles or gases, such as cigarette smoke or air pollution. However, studies have suggested that viral infections, including SARS, may also play a role in the development of COPD by causing chronic inflammation in the lungs. It is important to note that the long-term effects of SARS on lung health are still being studied, and more research is needed to fully understand the extent of the damage caused by the disease. However, the evidence so far suggests that SARS survivors may be at an increased risk of developing lung-related complications later in life, and it is important for healthcare providers to be aware of these risks when treating individuals who have recovered from the disease [5].

Conclusion

In conclusion, the long-term consequences of SARS on lung health are a growing concern. Survivors of the disease are at an increased risk of developing a range of lung-related complications, including COPD, pulmonary fibrosis, and respiratory failure. These complications may not be immediately apparent but can have serious implications for the health and quality of life of individuals who have recovered from SARS. As such, it is important for healthcare providers to be vigilant in monitoring the lung health of SARS survivors and to provide appropriate interventions to prevent or manage these complications.

References

1. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med.* 2003;348(20):1967-76.

*Correspondence to: Swenson Agarwal, Department of Medicine, University of Weill Cornell Medicine, New York, USA, E mail: agarwalswenson@med.cornell.edu

Received: 17-Mar-2023, Manuscript No. AAIJRM-23-95119; Editor assigned: 21-Mar-2023, PreQC No. AAIJRM-23-95119(PQ); Reviewed: 04-Apr-2023, QC No. AAIJRM-23-95119; Revised: 07-Apr-2023, Manuscript No. AAIJRM-23-95119(R); Published: 14-Apr-2023, DOI: 10.35841/aijrm-8.2.138

2. Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *Int J Antimicrob Agents*. 2020;55(3):105924.
3. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. *Lancet*. 2003;361(9366):1319-25.
4. van de Donk NW, Janmaat ML, Mutis T, et al. Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond. *Immunol Rev*. 2016;270(1):95-112.
5. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med*. 2020;180(7):934-43.

Citation: Agarwal S. The long-term consequences of severe acute respiratory syndrome (SARS) on lung health. *Int J Respir Med*. 2023;8(2):138